VivoSeq
Infectious Disease

HIV-Associated Nephropathy

5

Pipeline Programs↗

0

Active Trials↗

4

Companies Involved↗

HIV-associated nephropathy is an early-stage landscape with 5 programs across 4 companies. The most active players are Agouron Pharmaceuticals, Roche, Glaxo Dba Glaxosmithkline. 3 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

0/100

Mech. Concentration

40/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Agouron Pharmaceuticals

1 program

Phase 3Roche logo

Roche

1 program

ApprovedG

Glaxo Dba Glaxosmithkline

1 program

ApprovedK

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

1

clinical trials

Completed1 · 100%

Clinical Trials

Trial Activity

A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000819·54 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)